NASDAQ: BBNX

Beta Bionics, Inc.

Healthcare | Medical - Equipment & Services

No licensed closing price on file for BBNX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.51

Beta Bionics, Inc. (NASDAQ: BBNX) is a medical equipment and services company. Figures from SEC EDGAR; updated 2026-10-20 10:41 UTC.

What Beta Bionics, Inc. does

The company is a commercial-stage medical device manufacturer that designs and sells the iLet Bionic Pancreas, an automated insulin delivery system for people with diabetes. The iLet was cleared by the FDA for Type 1 diabetes treatment in adults and children six years and older and was commercially launched in May 2023, reaching an installed base of 35,011 units as of December 31, 2025. Unlike other insulin pumps, the iLet autonomously determines and delivers all insulin doses using adaptive closed-loop algorithms that integrate with continuous glucose monitors via Bluetooth.

Summarized from Beta Bionics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-05-22
EPS (TTM)	$-1.51

Revenue, margins & earnings

Net income
Taxes & interest
Operating expenses
Cost of revenue
Net loss year

Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-16

2026-10-16Chief Commercial OfficerSale-775$13.4K
2026-10-05Chief Commercial OfficerSale-370$7.0K
2026-09-23DirectorSale-6,430$147.9K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

EVENTIDE ASSET MANAGEMENT, LLC6,253,673$98.05M+5.2%
Soleus Capital Management, L.P.4,393,714$68.85M+0.9%
MORGAN STANLEY4,266,822$66.86M+0.9%

View QoQ ownership changes →Full institutional ownership →

Company news

View all →

BBNX Deadline Reminder: Beta Bionics Investors are Notified to Contact BFA Law before the Expiration of the November 3 Lead Plaintiff Deadline
globenewswire.com2026-10-19
Kaplan Fox & Kilsheimer LLP Encourages Beta Bionics, Inc. (BBNX) Investors With Losses to Seek Appointment as Lead Plaintiff Before November 3, 2026
newsfilecorp.com2026-10-19NEG
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
prnewswire.com2026-10-19
BBNX DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX
globenewswire.com2026-10-18
BBNX DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX
newsfilecorp.com2026-10-16

Questions this page answers

What does Beta Bionics, Inc. do?

The company is a commercial-stage medical device manufacturer that designs and sells the iLet Bionic Pancreas, an automated insulin delivery system for people with diabetes.

When did BBNX last file with the SEC?

Beta Bionics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 10:41 UTC. This page is also available as JSON at /api/data?ticker=BBNX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BBNX and 5,000+ tickers.

Create a free account — keep BBNX

For your agent

GET /api/data?ticker=BBNX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt